SurgX Antimicrobial Wound Gel for ST13 protein, human

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Long Island Jewish Medical Center, New Hyde Park, NY
ST13 protein, human+1 More
SurgX Antimicrobial Wound Gel - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a single-site, prospective, clinical study of subjects that are scheduled to undergo either total hip or total knee arthroplasties. It is anticipated that surgical wounds treated with SurgX will exhibit reduced surgical site complication rates and improved post-operative treatment outcomes by potentially decreasing site bioburden of both free-floating and biofilm-entrenched organisms.

Eligible Conditions

  • ST13 protein, human
  • Total Knee Arthroplasty (TKA)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 12 weeks after index procedure

Week 12
Wound images
Week 12
Surgical site complication

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Treatment Group
1 of 1
Experimental Treatment

700 Total Participants · 1 Treatment Group

Primary Treatment: SurgX Antimicrobial Wound Gel · No Placebo Group · N/A

Treatment Group
Other
Experimental Group · 1 Intervention: SurgX Antimicrobial Wound Gel · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks after index procedure
Closest Location: Long Island Jewish Medical Center · New Hyde Park, NY
Photo of new york 1Photo of new york 2Photo of new york 3
2007First Recorded Clinical Trial
0 TrialsResearching ST13 protein, human
149 CompletedClinical Trials

Who is running the clinical trial?

Northwell HealthLead Sponsor
409 Previous Clinical Trials
289,510 Total Patients Enrolled
Next ScienceUNKNOWN
1 Previous Clinical Trials
936 Total Patients Enrolled
Giles ScuderiPrincipal InvestigatorNorthwell Health
1 Previous Clinical Trials
936 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a male or female 18 years or older.
You are scheduled to undergo primary hip or knee arthroplasty.
You are willing and able to comply with all study procedures and be available for the duration of the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.